Aleksandra Dasic

Dr. Aleksandra Dasic

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
APAleksandra Plavsic
Aleksandra Plavsic
Rada MiskovicRada Miskovic
Rada Miskovic
DJDragana Jovanovic
Dragana Jovanovic
UKUros Karic
Uros Karic
ZJZikica Jovicic
Zikica Jovicic
SASnezana Arandjelovic Arandjelovic
Snezana Arandjelovic Arandjelovic
Macrophage activation syndrome (MAS) is a complex, life-threatening, hyperinflammatory condition occurring as a form of hemophagocytic lymphohistiocytosis (HLH), commonly associated with several autoimmune and autoinflammatory diseases, and certain infections such as Parvovirus B19 (P19V). The onset of systemic lupus erythematosus (SLE) presenting as MAS during pregnancy is uncommon, posing significant diagnostic and therapeutic challenges. We present a case of a 30-year-old woman at the 12th gestational week with fever, arthralgia, rash, cervical lymphadenopathy, cytopenia, and elevated liver enzyme. Bone marrow biopsy revealing hemophagocytosis, elevated ferritin and triglycerides, high interleukin-2, fever and cytopenia, confirmed the diagnosis of HLH. Further evaluation revealed the diagnosis of SLE. Treatment was initiated with intravenous immunoglobulin and corticosteroids. Given the deterioration in the patient’s clinical condition, a decision was made to terminate the pregnancy. She continued in the following months to receive SLE treatment with corticosteroids, cyclophosphamide, hydroxychloroquine, and later with mycophenolate mofetil due to the development of Class IV of lupus nephritis. P19V IgM antibodies were initially positive, later seroconverted to IgG, indicating that infection may have acted as a trigger for the onset of SLE and MAS development during pregnancy. The overlapping clinical features of P19V infection, SLE, and MAS pose significant diagnostic and therapeutic challenges. Early recognition and comprehensive diagnostic evaluation are crucial for the management of these conditions, especially during pregnancy, where both maternal outcomes are at risk.

9 September 2026 in Diseases
Verified
Journal Article
Open access
PDF file
ADAleksandra Dasic
Aleksandra Dasic
Dragan VasinDragan Vasin
Dragan Vasin
Maja StojanovicMaja Stojanovic
Maja Stojanovic
DJDragana Jovanovic
Dragana Jovanovic
AKAnja Kisic
Anja Kisic
Rada MiskovicRada Miskovic
Rada Miskovic
Sarcoidosis and granulomatosis with polyangiitis (GPA) are the most common non-infectious causes of granulomatous lung disease. However, they can sometimes be difficult to distinguish due to overlapping clinical, radiological, and histopathological features. A 54-year-old man was considered to have sarcoidosis in 2018. Treatment with glucocorticoids led to improvement, but the patient self-discontinued it in 2021. In January 2022, he was readmitted due to recurrent cough and fatigue, who then developed purpuric lesions on the lower extremities, renal impairment, and abnormal results for liver function tests. Chest computed tomography showed lymphadenopathy, consolidations, and nodular lesions. Liver and spleen lesions were detected on abdominal ultrasound, and liver biopsy was performed revealing necrotizing granulomas. Strongly positive proteinase 3 (PR3) anti-neutrophil cytoplasmic antibody (ANCA) together with clinical, radiological, and histopathological findings supported the diagnosis of GPA. Treatment with methylprednisolone and cyclophosphamide led to clinical and partial laboratory improvement. Unfortunately, the patient died suddenly, reportedly in association with massive hemoptysis. Ongoing reassessment during the disease course is essential for accurate diagnosis and optimal management. This case highlights the diagnostic challenges posed by overlapping features of sarcoidosis and GPA, and the rare presence of hepatic necrotizing granulomas with concurrent radiologically suspected granulomatous splenic involvement. The limited data reported in the literature make this case particularly unique and diagnostically significant.

2 April 2025 in Anti-Aging Eastern Europe
Verified
Journal Article
Open access
SRSara Radović
Sara Radović
AVAnja Vrljes
Anja Vrljes
ADAleksandra Dasic
Aleksandra Dasic
Maja StojanovicMaja Stojanovic
Maja Stojanovic
Rada MiskovicRada Miskovic
Rada Miskovic
Recent research indicates that the age of disease onset plays a crucial role in shaping the phenotype of systemic autoimmune inflammatory diseases. Late-onset Sjögren’s syndrome (SS) presents unique diagnostic challenges due to symptom overlap with age-related conditions. Key issues include difficulties in interpreting tests for sicca syndrome, high prevalence of comorbidities, polypharmacy, and underutilization of salivary gland biopsy in older patients. This narrative review provides an overview of the clinical and immunological characteristics of late-onset SS, along with management strategies tailored to this population. Emphasis is placed on the need for an age-adjusted diagnostic approach and the value of multidisciplinary, holistic care for late-onset SS patients.

1 January 2022 in Medicinska istrazivanja
Verified
Journal Article
Open access
PDF file
Rada MiskovicRada Miskovic
Rada Miskovic
ZJZikica Jovicic
Zikica Jovicic
VSVesna Tomic Spiric
Vesna Tomic Spiric
Maja StojanovicMaja Stojanovic
Maja Stojanovic
APAleksandra Plavsic
Aleksandra Plavsic
APAleksandra Perić-Popadić
Aleksandra Perić-Popadić
Introduction: Patients with refractory chronic spontaneous urticaria (CSU) may pose a significant challenge to the treating physician. Although many studies have investigated the effects of omalizumab in refractory CSU, many issues remain unanswered. Aim: To describe our experience in treating refractory CSU with omalizumab in a real-life setting. Material and methods: We present a series of eight patients with refractory CSU treated with omalizumab during a 2-year period. Results: The average duration of CSU was 49.9 months (3-180). A high average 7-day Urticaria Activity Score (UAS7) of 31.3 (12-42) and a low average Urticaria Control Test (UCT) score of 4.1 (0-8) had been recorded before omalizumab therapy. Prior to omalizumab, all patients required fourfold dose of H1-anihistamines, montelukast and corticosteroids to achieve at least a partial disease control. Antimalarial was given to two patients and dapsone to three, with no response. Adverse effects of corticosteroids were noted in most patients. Patients received 150 mg or 300mg of omalizumab subcutaneously every 4 weeks, for at least 3 months. All patients responded well to omalizumab and discontinued corticosteroid therapy. There were no significant side effects during omalizumab treatment. Conclusion: Omalizumab is an effective corticosteroid sparing treatment, enabling disease control in patients with refractory CSU, even in lower doses (150 mg) and when given for a short period of time. This is especially important when the availability of the drug is determined by economic issues.

1 January 2026 in Srpski medicinski casopis Lekarske komore
Verified
Journal Article
Open access
PDF file
ADAleksandra Dasic
Aleksandra Dasic
NRNebojsa Radovanovic
Nebojsa Radovanovic
MPMaja Prodanović
Maja Prodanović
MDMarija Dinić
Marija Dinić
Maja StojanovicMaja Stojanovic
Maja Stojanovic
Introduction/Objective: Macrophage activation syndrome (MAS) is a hyperinflam-matory syndrome and an extremely rare but potentially life-threatening complication of systemic lupus erythematosus (SLE), other systemic autoimmune and autoinflammatory diseases, infections, and malignancies. Case report: A 33-year-old female patient with a history of recurrent cholangitis since childhood and persistently positive antinuclear antibodies (ANA) for several years was treat-ed symptomatically in December 2022 for fever and gastrointestinal symptoms interpreted as a recurrent episode of cholangitis, despite the presence of pancytopenia, consumptive coagulopathy, and impaired renal function. In January 2023, she developed recurrent fever accompanied by peripheral lymphadenopathy, splenomegaly, progression of pancytopenia, and hypocomplementemia, at which point a diagnosis of SLE was established and treatment with methylprednisolone was initiated. Due to newly developed changes in mental status with hallucinations and prominent nightmare content, neuropsychiatric lupus was consid-ered; however, it was not confirmed because of the absence of an adequate neuroradiologi-cal correlate. Subsequently, progressive deterioration of liver and kidney function and wors-ening pancytopenia occurred, accompanied by extreme hyperferritinemia (> 33,511 µg/L), hypofibrinogenemia, and hypertriglyceridemia, leading to the diagnosis of macrophage activation syndrome as a complication of active, previously unrecognized systemic lupus ery-thematosus (H-score 266). Cyclosporine was introduced, resulting in transient improvement; however, despite immunomodulatory doses of intravenous immunoglobulins along with the other therapy, anasarca, respiratory, cardiac, and renal failure developed. Therapeutic plasma exchange and intensive ultrafiltration resulted in short-term clinical, laboratory, and echocardiographic improvement, followed by worsening of the multiple organ dysfunction syndrome. Despite all treatment modalities employed, the patient had a fatal outcome. Conclusion: The overlap of the clinical and laboratory manifestations of active systemic lupus erythematosus and macrophage activation syndrome significantly complicates timely diagnosis. Monitoring ferritin concentrations is of particular diagnostic impor-tance, with values > 10,000 µg/L considered highly suggestive of MAS.

31 August 2026 in Allergy
Verified
Journal Article
Open access
PDF file
MTMaría J Torres
María J Torres
MMMarina Atanasković Marković
Marina Atanasković Marković
AGAsli Gelincik
Asli Gelincik
Sophia TsabouriSophia Tsabouri
Sophia Tsabouri
IAIsabella Annesi-Maesano
Isabella Annesi-Maesano
MSMohamed H. Shamji
Mohamed H. Shamji
Click on the article title to read more.